A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG

This study is testing whether adding a drug called fruquintinib (a targeted therapy that blocks blood vessel growth in tumors) to standard chemotherapy helps prevent cancer from coming back in people with stomach or stomach-junction cancer that did not respond well to pre-surgery chemotherapy. 'Poor response' means the tumor did not shrink much during initial treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have stomach or gastroesophageal junction cancer confirmed by biopsy - Your cancer did not respond well to pre-surgery chemotherapy (Tumor Regression Grade 2 or 3) - You had successful surgery to remove the cancer (R0 resection) - You are in good general health (ECOG 0–1) - Your expected survival is at least 2 years **You may NOT be eligible if...** - You have had previous stomach cancer surgery - You have HER2-positive cancer - You have other serious health conditions that prevent surgery or chemotherapy Talk to your doctor to see if this trial is right for you.